Therapeutic efficacy and safety of sotoracib (AMG 510) in elderly patients with lung cancer

Sotorasib (Sotorasib) is a targeted drug targeting the KRAS G12C mutation, specifically used to treat patients with non-small cell lung cancer (NSCLC) who carry this mutation. For elderly patients, due to the decline in liver and kidney function caused by age and the existence of various underlying diseases, the selection of tumor treatment options needs to be extremely cautious. Clinical data shows that sotoracib can still exert significant anti-tumor effects in elderly patients, helping to delay disease progression and improve quality of life.

In terms of efficacy, after elderly patients with lung cancer are treated with sotoracib, the overall response rate (ORR) can reach about 30%-40%, and the median progression-free survival (PFS) is about 6-7 months. Although slightly lower than some younger patients, sotorasiib provides a safe and feasible targeted treatment option for the elderly group who cannot tolerate traditional chemotherapy. Some patients can observe a reduction in tumor burden and improvement in symptoms in a short period of time, showing rapid onset of action.

In terms of safety, sotoraxib was generally well tolerated in elderly patients. Common adverse reactions include mild to moderate increases in liver function parameters, diarrhea, fatigue, and musculoskeletal pain. Elderly patients need to pay more attention to liver and kidney function, blood routine and cardiovascular status, and adjust the dose or extend the dosing interval if necessary to reduce the risk of serious adverse events. The incidence of serious adverse events is low, but regular follow-up monitoring is still required.

Taken together, sotoracib has good efficacy and controllable safety in elderly KRAS G12C positive non-small cell lung cancer patients. When formulating treatment plans, doctors should conduct individualized management based on the patient's age, underlying diseases, and drug tolerance, while emphasizing regular follow-up and laboratory monitoring to optimize treatment effects and ensure the safety and quality of life of elderly patients in targeted therapy.

Reference link:https://www.drugs.com